tbuckley/cabot-search huggingface dataset:
FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
Authors: Vincent J. Picozzi, J. Marc Pipas, Albert Koong, Amato Giaccia, Nathan Bahary, Smitha S. Krishnamurthi, Charles D. Lopez, Peter J. O'Dwyer, Katharina Modelska, Mairead Carney, Heather Hernandez, James Chou, Tyson Lee, Ming Zhong, Seth Porter, Tom Neff, Frank Valone
Journal: Journal of Clinical Oncology (2014)

4138 Background: CTGF is overexpressed in PDAC and facilitates local desmoplasia, tumor survival and metastasis. FG-3019 is a CTGF-specific monoclonal antibody that decreases tumor growth and metastases and prolongs survival in the KPC mouse model of pancreatic cancer. This study evaluated safety and efficacy of FG-3019 with G/E in patients (Pts) with PDAC. Methods: FG-3019 was combined with G/E in Pts with previously untreated, measurable, Stage 3 or 4 PDAC. Cohorts 1−6 received FG-3019 Q2W at 3, 10, 15, 25, 35 or 45 mg/kg. Cohort 7 received 35 mg/kg on Day 1, then 17.5 mg/kg QW. Cohort 8 received 45 mg/kg on Day 1, then 22.5 mg/kg QW. Results: 75 Pts were enrolled. Baseline characteristics: Stage 3 / 4 (11/64); ECOG=0/1 (30/45). Median of 9 FG-3019 doses were administered (range: 1-73). FG-3019 was well tolerated with no DLT. MTD is > 45 mg/kg. Median OS was 9.4 months in the per-protocol population. Best RECIST response was 2(3%) CR, 8(11%) PR, 39(52%) SD, 12(16%) PD, (14 no RECIST data). OS generally correlated with FG-3019 exposure in Cycle 1. Day 15 Cmin ≥ 150 ug/mL was associated with improved OS (p=0.03) and 1 year survival (p=0.03). CA 19.9 response was 52% (Cmin ≥ 150) and 38% (Cmin < 150). Pts with ascites had low Cmin and poor OS. High FG-3019 doses with Cmin >150 ug/mL appeared to improve OS. Baseline plasma CTGF correlated inversely with OS (p=0.006). In bivariate analysis, Day 15 Cmin ≥ 150 ug/mL and baseline CTGF < median were associated with better survival (p=0.04 and 0.02 respectively). Greatest survival was in Pts with Day 15 Cmin> 150 ug/mL and baseline CTGF < median. Conclusions: FG-3019 did not add to toxicity of G/E. Results suggest OS improves with increasing exposure to FG-3019, and the combination of baseline CTGF and plasma FG-3019 levels could be a predictor of efficacy. Given its advantageous safety profile, FG-3019 could be combined with other chemotherapeutic regimens. Clinical trial information: NCT01181245. FG-3019 Day 15 Cmin (ug/mL) Baseline CTGF (ng/mL) Median OS (months) 1-year OS (%) ≥150 Any 9.4 34% < 150 Any 6.3 12% Any < median 10.4 31% ≥ median 4.8 13 % ≥150 < median 11.2 42% ≥ median 8.6 22% < 150 < median 8.0 19% ≥ median 3.8 6%
P1.16-17 The Role of Quantitative Metabolic Metrics on FDG-PET/CT in Predicting Pathological Invasive Factors in cN0 Lung Adenocarcinoma
Authors: T. Tanaka, Y. Shimada, Y. Makino, J. Maeda, M. Hagiwara, T. Okano, M. Kakihana, N. Kajiwara, T. Ohira, J. Matsubayashi, N. Ikeda
Journal: Journal of Thoracic Oncology (2018)
1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109)
Authors: M. Geissler, T. Klingler, J. Riera Knorrenschild, A. Tannapfel, J. Greeve, T. Seufferlein, S. Kanzler, S. Held, V. Heinemann, A. Reinacher-Schick, U.M. Martens
Journal: Annals of Oncology (2018)
Autoinflammation due to homozygous S208 <i>MEFV</i> mutation
Authors: Ying Hong, Ariane S I Standing, Sira Nanthapisal, Neil Sebire, Stephen Jolles, Ebun Omoyinmi, Ruud Hj Verstegen, Paul A Brogan, Despina Eleftheriou
Journal: Annals of the Rheumatic Diseases (2018)

Figure 1 Family tree, genetic sequencing results, proinflammatory cytokines and pyrin inflammasome activation in patients with homozygous p.S208T MEFV mutation.(A) The family tree shows the two affected male siblings and their unaffected sibling from the consanguineous marriage of first cousins; segregation of the p.S208T MEFV variant is also shown.(B) Sanger sequencing chromatogram of MEFV gene aligned to reference sequence exon 2 of MEFV.Line indicates a homozygous mutation of MEFV at position c.623 (red dashed box) present in both affected patients (IV-1and IV-2) and heterozygous in parents (III-1 and III-2) and unaffected sister (IV-3).(C) Serum levels of interleukin (IL)-1β were elevated in IV-1 and IV-2 (median 0.26 pg/mL, range 0.16-0.44pg/mL) compared with healthy controls (median 0 pg/mL, range of 0-0.08 pg/mL, p=0.005) and compared with their unaffected parents (III-2 and III-3), unaffected sibling (IV-3) all with WT/p.S208T MEFV genotype (median levels of 0.1 pg/mL, range of 0.08-0.12pg/mL, p=0.04).(D) Similar differences were observed for total IL-18 levels that were elevated in IV-1 and IV-2 compared with controls, p=0.01 and compared with III-1, III-2 and IV-3, p=0.05.(E) Monocytes from IV-1 and IV-2 constitutively expressed higher levels of FLICA (caspase-1) in response to lipopolysaccharide (LPS) (mean 398, SEM 84.63) compared with controls (mean 292.8, SEM 95.49, p=0.001) and when compared with heterozygotes for p.S208T MEFV mutation (mean 371.5, SEM 109.7,p=0.01).(F) There was an increased release of IL-1β in monocyte supernatants derived from IV-1 and IV-2 following LPS stimulation compared with healthy controls (p=0.001).No significant difference in IL-1β secretion was observed between healthy and patient monocytes after ATP and TcdB addition.(G) There was enhanced release of CCL5 in patient derived peripheral blood mononuclear cells (PBMC) stimulated with LPS (mean relative CCL-5 levels at 233, SEM 37.29 pg/mL) compared with controls (mean relative CCL-5 levels of 126.6, SEM 24.91 pg/mL, p=0.02).Similar differences were observed between groups in CCL-5 release in response to PMA/Ionomycin stimulation, p=0.001.Error bars represent medians and range or for in vitro experiments means+SEM for three biological replicates.P values by Student's t-test or Mann-Whitney U test <0.05 were considered significant.CCL-5, C-C-motif chemokine ligand 5; FLICA, fluorochrome inhibitor of caspases; PMA, phorbol 12-myristate13-acetate.
Interim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer
Authors: F. Saad, K.N. Chi, N. Shore, J.N. Graff, E.M. Posadas, S. Freeman, J. Tryon, G.C. Trudel, J. de Jong, J. Meltzer, X. Zhao, N. Tran, A. Rezazadeh
Journal: Annals of Oncology (2018)
NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer
Authors: V. Gambardella, F. Gimeno-Valiente, N. Tarazona, T. Fleitas Kanonnikoff, P. Tolosa, M. Belda Moscardò, B. Garcia-Mico, M. Huerta, S. Roselló, D. Roda, A. Cervantes, J. Castillo
Journal: Annals of Oncology (2018)
P1.01-17 Immune-Related Adverse Events in Patients with Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy
Authors: N. Duma, A. Azzouqa, S. Yadav, K. Hoversten, C. Reed, A. Sitek, E. Enninga, J. Paludo, J. Vera Aguilera, Y. Lou, J. Molina, K. Leventakos, L. Kottschade, H. Dong, A. Mansfield, R. Manochakian, R. Dronca, A. Adjei
Journal: Journal of Thoracic Oncology (2018)
EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer
Authors: Shun Lu, Yongfeng Yu, Ziming Li, Ruoying Yu, Xue Wu, Hairong Bao, Yan Ding, Yang W. Shao, Hong Jian
Journal: Journal of Thoracic Oncology (2019)
ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma
Authors: P.A. Ascierto, P. Arenberger, V.G. Atkinson, J. Hansson, E. Kapiteijn, C. Loquai, S. Negrier, H.M. Shaw, A. Tarhini, J. Walker, J. Geib, S. Rahimian, S. Swann, A. Diab
Journal: Annals of Oncology (2018)
JCSE01.22 Differential Molecular Mechanisms Associated with Dramatic and Gradual Progression in NSCLC Patients with Intrathoracic Dissemination
Authors: Y. Chen, B. Hua, W. Li, C. Zhang, W. Tang, A. Wang, X. Wu, J. Chen, J. Su, Y.W. Shao, Y. Wu, W. Zhong
Journal: Journal of Thoracic Oncology (2018)
Eribulin in metastatic breast cancer the UK experience: A multi-centre retrospective 577 patient study
Authors: M. Jafri, H. Kristeleit, V. Misra, M.A. Baxter, S. Ahmed, A. Jegnnathen, A. Jain, D. Maskell, U. Barthakur, G. Edwards, H. Walter, R. Walter, M.A. Khan, A. Borley, P. Nightingale, D. Rea
Journal: Annals of Oncology (2018)
The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)
Authors: K. Usui, T. Yokoyama, A. Kisohara, Y. Mori, Y. Takeda, H. Ishida, N. Kusano, K. Kishi, U. Katsushima, T. Kuwako, H. Aono, Y. Shikama, K. Minato, H. Matsushima, K. Uemura, Y. Ohashi, H. Kunitoh
Journal: Annals of Oncology (2018)
Phase II study of S-1 and oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601)
Authors: K. Kobayashi, M. Iwatsuki, H. Orita, S. Hidaka, T. Arigami, T. Kusumoto, H. Satake, E. Oki, K. Satoshi, K. Tobimatsu, M. Shimokawa, H. Saeki, A. Makiyama, Y. Kakeji, S. Natsugoe, H. Baba, S. Eguchi, Y. Maehara
Journal: Annals of Oncology (2018)
A phase II trial of docetaxel plus cisplatin in recurrent and/or metastatic non-squamous cell carcinoma of head and neck
Authors: Y. Imamura, N. Kiyota, K. Tanaka, H. Hayashi, I. Ota, K. Nario, S. Hirano, A. Arai, S. Iwae, T. Onoe, S. Minami, T. Shimada, K. Yane, T. Yamazaki, Y. Nagatani, M. Toyoda, N. Otsuki, K.-I. Nibu, H. Minami
Journal: Annals of Oncology (2018)
Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)
Authors: Y.Y. Elamin, M. Antonoff, C. Blakely, M. Baggstorm, T. Bivona, X. Le, A.V. Louie, R.C. Doebele, C. Rusthoven, P. Lee, R. Govindan, S.G. Swisher, V.A. Papadimitrakopoulou, J.V. Heymach, D.R. Gomez
Journal: Annals of Oncology (2018)
First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine+nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe
Authors: J. Taieb, A. Carrato, B. Westphalen, D. Melisi, G. Prager, T. Macarulla Mercade, ÅB.C. Mellbring, N. d'Esquermes, A. Ferreras, F. de Jong
Journal: Annals of Oncology (2018)
Voices of survivors: ‘you will not destroy our light’
Authors: Melissa D McCradden, Michael D Cusimano
Journal: British Journal of Sports Medicine (2018)

The horrors revealed in the Larry Nassar case—the US Olympic Team osteopathic doctor and team physician who sexually abused hundreds of female athletes over decades, are shocking, and it may easily be dismissed as an ‘extreme’ case. Yet it is important to note that certain elements of the Nassar situation shed critical light on the larger problem of how sport abuse can occur. To prevent future abuse, we have a moral obligation to listen to the survivors’ stories who were ignored for so long to understand how we may make sport safe for every athlete. This editorial describes narrative themes1 emerging from 150 victim impact statements heard at Nassar’s sentencing that spoke to elements of sport that facilitated the abuse.

One of the most powerful norms that silenced these athletes was that in gymnastics they were taught ‘not to question authority’ and to ‘hide emotions, control [their] feelings and keep a level head’. In many sports, there has traditionally been a pervasive notion that obedience leads to success. But why? Despite the advocacy for athlete-centred or humanist coaching methods, …
P1.05-01 Incidence and Clinical Relevance of NSCLC Lymph Node Micro-Metastasis Detected by Staging EBUS-TBNA
Authors: A. Belanger, J. Hollyfield, G. Yacovone, A. Seppe, J. Akulian, C. Burks, P. Rivera, L. Dodd, J. Long, B. Haithcock, C. Pecot
Journal: Journal of Thoracic Oncology (2018)
The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine-based chemotherapy
Authors: M.M. Skupinska, M. Jesiotr, P. Chrom, A. Mroz, S. Cierniak, M. Winiarek, L.S. Wyrwicz, J. Pieczykolan, M. Wieczorek, A. Stanczak, L. Bodnar
Journal: Annals of Oncology (2018)
P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review
Authors: K. Winfree, C. Ainsworth, A. Njue, C. Molife, M. Lyall, M. Jen, M. Bittoni, A. Heyes, D. Carbone
Journal: Journal of Thoracic Oncology (2018)
Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Authors: J. Garcia, A. Delherme, F. Geigeur, P. Merle, C. Tissot, F.S. Jones, D. Edelstein, P.-J. Souquet, C. Rodriguez-Lafrasse, S. Couraud, L.F. Payen, Z. Xu
Journal: Annals of Oncology (2018)
Dual Polymerizations: Untapped Potential for Biomaterials
Authors: Daniel C. Lee, Robert J. Lamm, Alex N. Prossnitz, Andrew J. Boydston, Suzie H. Pun
Journal: Advanced Healthcare Materials (2018)

Block copolymers with unique architectures and those that can self-assemble into supramolecular structures are used in medicine as biomaterial scaffolds and delivery vehicles for cells, therapeutics, and imaging agents. To date, much of the work relies on controlling polymer behavior by varying the monomer side chains to add functionality and tune hydrophobicity. Although varying the side chains is an efficient strategy to control polymer behavior, changing the polymer backbone can also be a powerful approach to modulate polymer self-assembly, rigidity, reactivity, and biodegradability for biomedical applications. There are many developments in the syntheses of polymers with segmented backbones, but these developments are not widely adopted as strategies to address the unique constraints and requirements of polymers for biomedical applications. This review highlights dual polymerization strategies for the synthesis of backbone-segmented block copolymers to facilitate their adoption for biomedical applications.
Air pollution: ban schools and other children’s facilities from hotspots, say campaigners
Authors: Zosia Kmietowicz
Journal: BMJ (2018)

New schools, nurseries, and playgrounds should not be built in air pollution hotspots, and existing ones should be surrounded by traffic exclusion zones to reduce children’s exposure to pollutants, a new campaign group has said.

The National Clean Air for Children Programme, which launched on 24 October, called for £153m (€173m; $197m) of government funding to help protect children from air pollution. Drawn up by the Clean Air Parents’ Network with support from the environmental law organisation ClientEarth and the British Lung Foundation, it also has the backing of the Royal College of Paediatrics and Child Health, the National Education Union, and Asthma UK.

The programme wants the air quality …
Clinical impact of whey protein and nutritional counseling in gastrointestinal cancer patients
Authors: M. Roberto, E. Sarfati, M. Di Girolamo, F.M. Schipilliti, E. Crimini, A. Botticelli, L. Marchetti, M. Muscaritoli, P. Marchetti, F. Mazzuca
Journal: Annals of Oncology (2018)
Role of pioglitazone on gene/protein expression profile, bioenergetics and TGFβ/SMAD signaling pathway in NSCLC
Authors: R. Di Liello, G. Viscardi, V. Ciaramella, G. Barra, G. Esposito, M. Fasano, F. Ciardiello, F. Morgillo
Journal: Annals of Oncology (2018)
MA09.06 The Newly Recognized Filigree Pattern of Micropapillary (MIP) Lung Adenocarcinoma (LADC) is as Clinically Important as the Classical Pattern
Authors: K. Emoto, T. Eguchi, R. Vaghjiani, Y. Takahashi, N. Rekhtman, P. Adusumilli, W. Travis
Journal: Journal of Thoracic Oncology (2018)
Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review
Authors: H.S. Rugo, G. Curigliano, F. Cardoso, W.J. Gradishar, M. Pegram, C.H.H. Barrios, J. Cortes Castan, E. Pennella, R. Muniz
Journal: Annals of Oncology (2018)
Molecular analysis of NRAS, BRAF, C-KIT, ROS1, ALK and RET alterations in serial biopsies in sinonasal mucosal melanoma
Authors: G. Anguera Palacios, L.P. del Carpio, M.-A. Molina, C. Aguado, J.R. Gras-Cabrerizo, X. Leon, M. Gonzalez-Cao, N. Karachaliou, A. Mozos, A. Gonzalez, A. Barnadas, R. Rosell, M. Majem
Journal: Annals of Oncology (2018)
Lessons From ARDS for Non-ARDS Research
Authors: Gordon D. Rubenfeld, Manu Shankar-Hari
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P1.01-24 Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy
Authors: D. Glick, E. Wai, M. Lesperance, N. Croteau, E. Brooks, D. Fenton, L. Fiorino, G. Geller, Z. Poonja, D. Ksienski
Journal: Journal of Thoracic Oncology (2018)
Late-Onset T1DM and Older Age Predict Risk of Additional Autoimmune Disease
Authors: Jing W. Hughes, Yicheng K. Bao, Maamoun Salam, Prajesh Joshi, C. Rachel Kilpatrick, Kavita Juneja, David Nieves, Victoria Bouhairie, Olivia J. Jordan, Erica C. Blustein, Garry S. Tobin, Janet B. McGill
Journal: Diabetes Care (2018)

Type 1 diabetes (T1DM) is associated with other autoimmune diseases (AIDs), which may have serious health consequences. The epidemiology of AIDs in T1DM is not well defined in adults with T1DM. In this cross-sectional cohort study, we sought to characterize the incident ages and prevalence of AIDs in adults with T1DM across a wide age spectrum.A total of 1,212 adults seen at the Washington University Diabetes Center from 2011 to 2018 provided informed consent for the collection of their age, sex, race, and disease onset data. We performed paired association analyses based on age at onset of T1DM. Multivariate logistic regression was used to evaluate the independent effects of sex, race, T1DM age of onset, and T1DM duration on the prevalence of an additional AID.Mean ± SD age of T1DM onset was 21.2 ± 14.4 years. AID incidence and prevalence increased with age. Female sex strongly predicted AID risk. The most prevalent T1DM-associated AIDs were thyroid disease, collagen vascular diseases, and pernicious anemia. T1DM age of onset and T1DM duration predicted AID risk. Patients with late-onset T1DM after 30 years of age had higher risks of developing additional AIDs compared with patients with younger T1DM onset.The prevalence of AIDs in patients with T1DM increases with age and female sex. Later onset of T1DM is an independent and significant risk factor for developing additional AIDs. Individuals who are diagnosed with T1DM at older ages, particularly women, should be monitored for other autoimmune conditions.
Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial
Authors: Y. Yu, M. Elmeliegy, J.K. Litton, I.C. Tudor, A. Czibere, J. Zheng, D.D. Wang
Journal: Annals of Oncology (2018)
Proof-of-concept study evaluating a new tool for standardising radiological assessment of tumour response to treatment in routine clinical practice
Authors: C. Mastier, C. de la Fouchardière, J. Fayette, M. Sarabi, P. Heudel, A. Coulon, N. Banaste, E. Mercier-Bischoff, M. Barma, M. Brahmi, P. Cassier, S. Couchon Thaunat, L. Eberst, G. Fournier-Garin, P. Metral, F. Pilleul, J.-Y. Blay
Journal: Annals of Oncology (2018)
Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ)
Authors: N. Martinez Lago, S. Candamio Folgar, C. Grande Ventura, M. Salgado Fernandez, J. De la Camara Gomez, J.C. Méndez Méndez, D. Arias Ron, F. Vazquez, M. Reboredo Lopez, Y. Vidal Ínsua, B. Graña Suarez, M. Jorge Fernandez, M.E. Brozos Vazquez, M.L. Pellon Augusto, J. Prato Varela, P. Gonzalez Villarroel, A. Fernandez Montes
Journal: Annals of Oncology (2018)
P1.14-16 DNA Methylation of GNG4、GHSR、HOXD9 and SALL3 Genes Predict Malignant Behavior of Thymic Epithelial Tumors
Authors: K. Kondo, R. Kishibuchi, S. Soejima, M. Tsuboi, K. Kajiura, Y. Kawakami, N. Kawakita, T. Sawada, H. Toba, M. Yoshida, H. Takizawa, A. Tangoku
Journal: Journal of Thoracic Oncology (2018)
Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels
Authors: K. Quinn, E. Helman, T. Nance, C. Artieri, J. Yen, J. Zhao, S. Fairclough, M. Sikora, D. Chudova, R.B. Lanman, A. Talasaz
Journal: Annals of Oncology (2018)
Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)
Authors: L. Miller-Phillips, L. Fischer von Weikersthal, F. Kaiser, S.-E. Al-Batran, T. Heintges, D. Neureiter, C. Kahl, F. Kullmann, M. Moehler, W. Scheithauer, C. Vazart, K. Fontaine, S. Held, D.P. Modest, J. Neumann, A. Jung, T. Kirchner, V. Heinemann, S. Stintzing
Journal: Annals of Oncology (2018)
Lung cancers carrying distinct ALK fusion variants demonstrate similar responsiveness to ALK tyrosine kinase inhibitors
Authors: E.N. Imyanitov, N.V. Mitiushkina, V.I. Tiurin, A.G. Iyevleva, M. Holmatov, E. Filippova, F. Moiseyenko, N. Levchenko, S. Odintsova, A. Lozhkina, A.V. Togo, N. Karaseva, V.M. Moiseyenko, S. Orlov
Journal: Annals of Oncology (2018)
OA07.07 PFS and OS Beyond 5 years of NSCLC Patients with Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)
Authors: D. De Ruysscher, R. Wanders, L. Hendriks, A. Van Baardwijk, B. Reymen, R. Houben, G. Bootsma, C. Pitz, A. Dingemans
Journal: Journal of Thoracic Oncology (2018)
Supporting caregivers during hematopoietic cell transplantation for children with primary immunodeficiency disorders
Authors: Jennie Yoo, Meghan C. Halley, E. Anne Lown, Veronica Yank, Katherine Ort, Morton J. Cowan, Morna J. Dorsey, Heather Smith, Sumathi Iyengar, Christopher Scalchunes, Christina Mangurian
Journal: Journal of Allergy and Clinical Immunology (2018)
Oral cavity immune response in pancreatic ductal adenocarcinoma (PDAC)
Authors: J.P. Marquez, P.A. Lucero-Diaz, J.A. Matute-Briseno, M.O. Rosas-Delgado, A. Camacho-Hernandez, Y. Cortez-Vargas, I. Nava-Sanchez, G.T. Montano, L.N. Montijo-Fernandez, M.A. Perez-Astorga
Journal: Annals of Oncology (2018)
P2.09-24 MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
Authors: H. Yu, R. Mosher, K. Ellison, P. Shaw, R. Dziadziuszko, E. Hailman, C. Rivard, F. Hirsch
Journal: Journal of Thoracic Oncology (2018)
Effectiveness of surgical glove compression therapy as a prophylactic method against nab-paclitaxel induced peripheral neuropathy
Authors: S. Tsuyuki, K. Yamagami, H. Yoshibayashi, T. Sugie, Y. Mizuno, S. Tanaka, H. Kato, T. Okuno, N. Ogura, H. Yamashiro, H. Takuwa, Y. Kikawa, T. Hashimoto, T. Kato, S. Takahara, A. Yamauchi, T. Inamoto
Journal: Annals of Oncology (2018)